Browse the evidence

Concerns regarding operative risks, irreversibility, and excess costs limit the broader clinical use of metabolic and bariatric surgeries.

Practitioners should be aware of these concerns when discussing surgical options with patients.

Continuation of GLP-1RAs did not appear to be associated with an increased incidence of residual gastric contents during EGD.

Practitioners can consider continuing GLP-1RAs during EGD without increased risk of residual gastric contents.

Rates of early termination of EGD were similar between groups.

Practitioners can expect similar rates of early termination of EGD regardless of GLP-1RA continuation.

There were no aspiration events in either group.

Practitioners can be reassured that there is no increased risk of aspiration events with GLP-1RA use during EGD.

The findings support nephroprotective mechanisms of GLP-1RAs independent of body weight and glycemic control.

This indicates that GLP-1RAs may be beneficial for kidney health beyond their metabolic effects.

The prevalence of obesity in the United States is 35.0% for men and 40.4% for women based on 2013 to 2014 national survey data.

Health practitioners should be aware of the significant prevalence of obesity in the population.

Body mass index (BMI) requirements for gender-affirming surgeries (GAS) present an obstacle to gender transition for many transgender and gender diverse (TGD) people.

Clinicians should be aware of the BMI-related barriers faced by TGD patients when considering GAS.

There is limited evidence supporting the effectiveness of n-3-PUFA supplementation in improving or preventing loss of lean mass in both younger and older healthy adults, as well as clinical populations including oncologic patients.

Practitioners should be cautious in recommending n-3-PUFA supplementation for lean mass improvement.

Most systematic reviews concluded that n-3-PUFA supplementation did not significantly affect strength.

Strength training recommendations should not rely on n-3-PUFA supplementation.

There was no consistent impact of n-3-PUFA supplementation on functional outcome measures.

Functional improvements should not be expected from n-3-PUFA supplementation.

In China, there was no significant association between white rice intake and diabetes risk (HR: 1.05; 95% CI: 0.78-1.41, p for trend=0.38).

Dietary recommendations regarding rice consumption may not apply uniformly across different populations, such as in China.

There are key knowledge gaps regarding long-term complications, microvascular and macrovascular events, and mortality associated with RYGB.

Further research is needed to understand the long-term risks associated with RYGB.

No statistically significant associations were identified for SGLT2 inhibitors regarding hematologic malignancy risk.

SGLT2 inhibitors may not pose a risk for hematologic malignancies, making them a safer choice in this regard.

BGM1812 was developed through a step-by-step modification process guided by structure-based drug design and molecular dynamics simulations.

Understanding the development process can inform future drug design strategies.

The study highlights a persistently elevated pulmonary aspiration risk in patients receiving semaglutide.

Anesthesiologists should be cautious of the increased aspiration risk in patients on semaglutide during surgery.

Up to 40% of adults in the United States have metabolic dysfunction-associated steatotic liver disease (MASLD).

Practitioners should be aware of the high prevalence of MASLD in adult patients.

Metabolic dysfunction-associated steatohepatitis is now a leading indication for liver transplantation.

Healthcare providers should consider MASLD as a critical factor in liver transplant evaluations.

GLP-1 receptor-based agonists and oral dipeptidyl peptidase-4 inhibitors are currently the only available treatments for metabolic diseases.

Practitioners should be aware that current treatment options are limited to GLP-1 receptor-based therapies.

Current GLP-1-based therapies face challenges such as high costs and the need for repeated administration.

Healthcare providers should consider these challenges when prescribing GLP-1 therapies.

Research is ongoing to develop improved GLP-1-based therapies, including oral small-molecule agonists and novel drug delivery strategies.

Practitioners should stay informed about emerging GLP-1 therapies that may improve patient compliance.

The quality of existing clinical evidence from anti-obesity trials generally ranges from low to moderate.

Practitioners should be cautious in interpreting the effectiveness of current anti-obesity medications due to the low to moderate quality of evidence.

Most trials suffered from publication bias.

Practitioners should be aware of potential biases in the published literature on anti-obesity drugs.

Additional higher-quality clinical trials are needed to gain more confidence in the estimate of the effect of currently used anti-obesity medicines.

Practitioners should advocate for and support the conduct of higher-quality trials to improve treatment options for obesity.

There is a better understanding of biomolecules related to obesity, including gut hormones and fat utilization.

Practitioners should consider the role of biomolecules in obesity management.